Literature DB >> 25062690

ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease.

Christopher Lathen1, Yu Zhang1, Jennifer Chow1, Martanday Singh1, Grace Lin1, Vishal Nigam1, Yasser A Ashraf1, Jason X Yuan1, Ivan M Robbins1, Patricia A Thistlethwaite2.   

Abstract

BACKGROUND: Pulmonary veno-occlusive disease is caused by excessive cell proliferation and fibrosis, which obliterate the lumen of pulmonary venules, leading to pulmonary hypertension, right ventricular failure, and death. This condition has no effective treatment and a 5-year survival of <5%. Understanding the mechanism of this disease and designing effective therapies are urgently needed. METHODS AND
RESULTS: We show that mice with homozygous deletion of the Ets transcription factor Erg die between embryonic day 16.5 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancytopenia. We demonstrate that Erg binds to and serves as a transcriptional activator of the G-protein-coupled receptor gene Aplnr, the expression of which is uniquely specific for venous endothelium and that knockout of either Erg or Aplnr results in pulmonary venule-specific endothelial proliferation in vitro. We show that mice with either homozygous-global or endothelium-directed deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectable at 8 months of age. Levels of pulmonary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation were significantly lower than those of control subjects.
CONCLUSIONS: Our results suggest that ERG and APLNR are essential for endothelial homeostasis in venules in the lung and that perturbation in ERG-APLNR signaling is crucial for the development of pulmonary veno-occlusive disease. We identify this pathway as a potential therapeutic target for the treatment of this incurable disease.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  hypertension, pulmonary; pulmonary veins; pulmonary veno-occlusive disease

Mesh:

Substances:

Year:  2014        PMID: 25062690      PMCID: PMC4182129          DOI: 10.1161/CIRCULATIONAHA.113.007822

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

1.  Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation.

Authors:  M Baltzinger; A M Mager-Heckel; P Remy
Journal:  Dev Dyn       Date:  1999-12       Impact factor: 3.780

2.  Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation.

Authors:  F McLaughlin; V J Ludbrook; J Cox; I von Carlowitz; S Brown; A M Randi
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

3.  Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2alpha kinase.

Authors:  J J Berlanga; J Santoyo; C De Haro
Journal:  Eur J Biochem       Date:  1999-10

4.  Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors.

Authors:  Vivien Schacht; Soheil S Dadras; Louise A Johnson; David G Jackson; Young-Kwon Hong; Michael Detmar
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

5.  The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation.

Authors:  Leon H Parker; Maike Schmidt; Suk-Won Jin; Alane M Gray; Dimitris Beis; Thinh Pham; Gretchen Frantz; Susan Palmieri; Kenneth Hillan; Didier Y R Stainier; Frederic J De Sauvage; Weilan Ye
Journal:  Nature       Date:  2004-04-15       Impact factor: 49.962

6.  The msr/apj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature.

Authors:  Magali Saint-Geniez; Claire Brand Argence; Bernard Knibiehler; Yves Audigier
Journal:  Gene Expr Patterns       Date:  2003-08       Impact factor: 1.224

7.  Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure.

Authors:  Kwok Shiong Chong; Roy S Gardner; James J Morton; Euan A Ashley; Theresa A McDonagh
Journal:  Eur J Heart Fail       Date:  2006-02-07       Impact factor: 15.534

8.  Apelin has in vivo inotropic effects on normal and failing hearts.

Authors:  Mark F Berry; Timothy J Pirolli; Vasant Jayasankar; Jeffrey Burdick; Kevin J Morine; Timothy J Gardner; Y Joseph Woo
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

9.  Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats.

Authors:  Xing Cheng; Xiao Shuo Cheng; Catherine C Y Pang
Journal:  Eur J Pharmacol       Date:  2003-06-06       Impact factor: 4.432

10.  EIF2AK4 mutations in pulmonary capillary hemangiomatosis.

Authors:  D Hunter Best; Kelli L Sumner; Eric D Austin; Wendy K Chung; Lynette M Brown; Alain C Borczuk; Erika B Rosenzweig; Pinar Bayrak-Toydemir; Rong Mao; Barbara C Cahill; Henry D Tazelaar; Kevin O Leslie; Anna R Hemnes; Ivan M Robbins; C Gregory Elliott
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

View more
  20 in total

Review 1.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

2.  SoxF factors induce Notch1 expression via direct transcriptional regulation during early arterial development.

Authors:  Ivy Kim-Ni Chiang; Martin Fritzsche; Cathy Pichol-Thievend; Alice Neal; Kelly Holmes; Anne Lagendijk; Jeroen Overman; Donatella D'Angelo; Alice Omini; Dorien Hermkens; Emmanuelle Lesieur; Ke Liu; Indrika Ratnayaka; Monica Corada; George Bou-Gharios; Jason Carroll; Elisabetta Dejana; Stefan Schulte-Merker; Benjamin Hogan; Monica Beltrame; Sarah De Val; Mathias Francois
Journal:  Development       Date:  2017-06-15       Impact factor: 6.868

3.  Linking Vascular Remodeling and Inflammation in Pulmonary Arterial Hypertension: Is There a Common Root Cause?

Authors:  Patricia A Thistlethwaite
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

4.  Systems Genetics in Human Endothelial Cells Identifies Non-coding Variants Modifying Enhancers, Expression, and Complex Disease Traits.

Authors:  Lindsey K Stolze; Austin C Conklin; Michael B Whalen; Maykel López Rodríguez; Kadri Õunap; Ilakya Selvarajan; Anu Toropainen; Tiit Örd; Jin Li; Anna Eshghi; Alice E Solomon; Yun Fang; Minna U Kaikkonen; Casey E Romanoski
Journal:  Am J Hum Genet       Date:  2020-05-21       Impact factor: 11.025

Review 5.  Regulation of the Apelinergic System and Its Potential in Cardiovascular Disease: Peptides and Small Molecules as Tools for Discovery.

Authors:  Sanju Narayanan; Danni L Harris; Rangan Maitra; Scott P Runyon
Journal:  J Med Chem       Date:  2015-07-10       Impact factor: 7.446

6.  The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1.

Authors:  Daniel N Meijles; Sanghamitra Sahoo; Imad Al Ghouleh; Jefferson H Amaral; Raquel Bienes-Martinez; Heather E Knupp; Shireen Attaran; John C Sembrat; Seyed M Nouraie; Mauricio M Rojas; Enrico M Novelli; Mark T Gladwin; Jeffrey S Isenberg; Eugenia Cifuentes-Pagano; Patrick J Pagano
Journal:  Sci Signal       Date:  2017-10-17       Impact factor: 8.192

7.  Letter by Papangeli et al Regarding Article, "The ERG-APLNR Axis Controls Pulmonary Venule Endothelial Proliferation in Pulmonary Veno-Occlusive Disease".

Authors:  Irinna Papangeli; Bikram Sharma; Hyung J Chun
Journal:  Circulation       Date:  2015-07-14       Impact factor: 29.690

8.  Response to Letter Regarding Article, "The ERG-APLNR Axis Controls Pulmonary Venule Endothelial Proliferation in Pulmonary Veno-Occlusive Disease".

Authors:  Christopher Lathen; Yu Zhang; Jennifer Chow; Martanday Singh; Grace Lin; Vishal Nigam; Yasser A Ashraf; Jason X Yuan; Ivan M Robbins; Patricia A Thistlethwaite
Journal:  Circulation       Date:  2015-07-14       Impact factor: 29.690

Review 9.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

10.  Discovery of a novel small molecule agonist scaffold for the APJ receptor.

Authors:  Sanju Narayanan; Rangan Maitra; Jeffery R Deschamps; Katherine Bortoff; James B Thomas; Yanyan Zhang; Keith Warner; Vineetha Vasukuttan; Ann Decker; Scott P Runyon
Journal:  Bioorg Med Chem       Date:  2016-06-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.